GoodRx Holdings, Inc. GDRX Prescription transactions revenue — Selling expense

Similar metrics at other companies

AMEEIG — Selling expense

$149.81M+24.4%

AMEEMG — Selling expense

$23.04M+5.7%

UHALSelling Expense

$71.75M-0.6%

UMH

UMHSelling Expense

$2.34M+26.5%

NUVBSelling Expense

$911K+430%

TGLSSelling Expense

$45.08M+51.6%

FAQ

What is GoodRx Holdings, Inc.'s prescription transactions revenue — selling expense?

GoodRx Holdings, Inc. (GDRX) reported prescription transactions revenue — selling expense of $2.8M in Q4 2025.

How has GoodRx Holdings, Inc.'s prescription transactions revenue — selling expense changed year-over-year?

GoodRx Holdings, Inc.'s prescription transactions revenue — selling expense decreased by 2.6% year-over-year, from $2.88M to $2.8M.

What does prescription transactions revenue — selling expense mean?

This metric captures the direct costs associated with selling activities specifically attributable to the prescription transactions segment, such as commissions or direct sales force compensation. It provides insight into the variable cost structure required to maintain and expand the transaction-based revenue stream. Monitoring this expense helps assess the operational efficiency and the cost-to-serve ratio for the company's core prescription business.